1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Glipizide |
| brand | String | Glucotrol, Glucotrol XL |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Sulfonylureas|Sulfonylurea (second-generation)]] • [[:Category:Insulin_secretagogues|Insulin secretagogue]] • [[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] |
| mechanism | String | '"`UNIQ--vote-000002D7-QINU`"' Hypoglycemia is the central risk, especially in elderly and renally impaired patients (glipizide has shorter half-life than glyburide, which is one reason it is preferred in older adults). CYP2C9 substrate; weight gain typical. |
| uses | String | '"`UNIQ--vote-000002D8-QINU`"' |
| starting_dose | String | 5 mg PO once daily, 30 minutes before breakfast; XL: 5 mg with breakfast |
| preparations | String | 5 mg, 10 mg immediate-release tablets; 2.5 mg, 5 mg, 10 mg extended-release tablets |
| fda_max | String | 40 mg/d (IR; doses >15 mg given as divided BID); 20 mg/d (XL) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Within 30 minutes (IR) |
| duration | String | ~12-24 hours |
| halflife | String | 2-5 hours'"`UNIQ--ref-000002D9-QINU`"' |
| bioavailability | String | ~100% (oral; food delays absorption, hence pre-meal dosing for IR)'"`UNIQ--ref-000002DA-QINU`"' |
| pregnancy | String | Avoid; switch to insulin. Hypoglycemia in newborn reported.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
